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The vaccine safety surveillance system effectively detected a very rare adverse event, narcolepsy, in
subjects receiving AS03-adjuvanted A(H1N1) pandemic vaccine made using the European inactivation/
puriﬁcation protocol. The reports of increased cases of narcolepsy in non-vaccinated subjects infected
with wild A(H1N1) pandemic inﬂuenza virus suggest a role for the viral antigen(s) in disease develop-
ment. However, additional investigations are needed to better understand what factor(s) in wild inﬂu-
enza infection trigger(s) narcolepsy in susceptible hosts. An estimated 31 million doses of European
AS03-adjuvanted A(H1N1) pandemic vaccine were used in more than 47 countries. The Canadian AS03-
adjuvanted A(H1N1) pandemic vaccine was used with high coverage in Canada where an estimated 12
million doses were administered. As no similar narcolepsy association has been reported to date with the
AS03-adjuvanted A(H1N1) pandemic vaccine made using the Canadian inactivation/puriﬁcation protocol,
this suggests that the AS03 adjuvant alone may not be responsible for the narcolepsy association. To date,
no narcolepsy association has been reported with the MF59-adjuvanted A(H1N1) pandemic vaccine.
This review article provides a brief background on narcolepsy, outlines the different types of vaccine
preparations including the ones for inﬂuenza, reviews the accumulated evidence for the safety of ad-
juvants, and explores the association between autoimmune diseases and natural infections. It concludes
by assimilating the historical observations and recent clinical studies to formulate a feasible hypothesis
on why vaccine-associated narcolepsy may not be solely linked to the AS03 adjuvant but more likely be
linked to how the speciﬁc inﬂuenza antigen component of the European AS03-adjuvanted pandemic
vaccine was prepared. Careful and long-term epidemiological studies of subjects who developed nar-
colepsy in association with AS03-adjuvanted A(H1N1) pandemic vaccine prepared with the European
inactivation/puriﬁcation protocol are needed.
 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Introduction
With the declaration of a global A(H1N1) inﬂuenza pandemic in
June 2009, mass vaccination campaigns using newly developed
monovalent A(H1N1) pandemic vaccines were initiated in aBY-NC-ND license (http://
S. Ahmed), pschur@partners.
Donald), steinman@stanford.
Ltd. Open access under CC BY-NC-NDnumber of countries using a range of vaccines developed with
different technologies [1]. In Europe, of the eight A(H1N1)
pandemic vaccines licensed during the 2009 pandemic, three were
authorized through the central procedure in the European Union
(EU) under the European Medicines Agency (EMA) and the Euro-
pean Commission and included one adjuvanted with AS03, one
adjuvanted with MF59, and one without adjuvant [1]. In the
United States, the Food and Drug Administration (FDA) authorized
four non-adjuvanted and one live, attenuated vaccine [2]. In Can-
ada, Health Canada authorized one AS03-adjuvanted A(H1N1)
pandemic vaccine [3] and one non-adjuvanted A(H1N1) pandemic license. 
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options offered and the ﬁnal recommended target groups varied in
different EU countries, in the United States, and in Canada with
most following the recommendations of the World Health Orga-
nization. In the European Union and European Economic Area
countries, more than 30.5 million doses of the AS03-adjuvanted
A(H1N1) pandemic vaccine, more than 6.5 million doses of the
MF59-adjuvanted A(H1N1) pandemic vaccine, and more than
560,000 doses of nonadjuvanted A(H1N1) pandemic vaccine were
sold and distributed [5]. Almost one year after their authorization,
an increase in narcolepsy cases was associated with the European
AS03-adjuvanted A(H1N1) pandemic vaccine raising major public
concerns about the safety of adjuvanted vaccines.
Despite diligence in safety monitoring prior to authorization,
the introduction of any new health intervention such as a drug, a
vaccine, or a medical device cannot exclude the risk for a rare
adverse event linked to the chemical/biological/mechanical com-
ponents of the product, to genetic susceptibilities in certain sub-
jects, or to environmental triggers. With very rare adverse events
(deﬁned as one in 10,000 vaccinations [1]), a signal may be
detectable only after the product, a vaccine for example, is intro-
duced into larger populations than those tested in pre-licensure
trials. A major challenge with rare events is the determination of
whether they are due to the product (e.g., vaccine) or just a coin-
cidental occurrence in that population [6]. To help address this, the
European Centre of Disease Prevention and Control (ECDC) funded
in 2008 a network of researchers called the Vaccine Adverse Event
Surveillance and Communication (VAESCO) consortium to establish
a European vaccine safety datalink in which rare adverse events
could be aggregated to better investigate related safety concerns [7]
similar to a model established across several US states [8]. VAESCO
was to be used to develop age- and sex-speciﬁc background inci-
dence data on rare and more common conditions in larger Euro-
pean populations which were anticipated to be of value in the
setting of mass vaccination campaigns such as the inﬂuenza
A(H1N1) pandemic virus in 2009 [9].
Narcolepsy associated with European AS03-adjuvanted
A(H1N1) pandemic vaccine was a very rare event. This article
provides a brief background on narcolepsy, outlines the different
types of vaccine preparations including the ones for inﬂuenza, re-
views the accumulated evidence for the safety of adjuvants, and
explores the association between autoimmune diseases and natural
infections. It concludes with a hypothesis on why vaccine-
associated narcolepsy may not be solely linked to the AS03Table 1
List of adjuvanted and non-adjuvanted 2009 A(H1N1) inactivated monovalent
vaccines and live, attenuated vaccine approved by European Medicine Agency, Food
and Drug Administration, and Health Canada.
Regulatory agency Adjuvant Product name (or manufacturer





e Celvapan (Baxter AG)





e ID Biomedical Corporation of Quebec
e Novartis Vaccines and Diagnostics
Limited
e Sanoﬁ Pasteur, Inc.
e Medimmune LLCc
Health Canada [3,4] AS03a Arepanrix (GlaxoSmithKline Inc)
e GlaxoSmithKline Inc
a AS03 ¼ 11.86 mg DL a-tocopherol, 10.69 mg squalene, 4.86 mg polysorbate 80.
b MF59 ¼ 1.175 mg sorbitan trioleate, 9.75 mg squalene, 1.175 mg polysorbate
80.
c Live, attenuated A(H1N1) 2009 pandemic vaccine.adjuvant but more likely be linked to how the speciﬁc inﬂuenza
antigen component of the European AS03-adjuvanted A(H1N1)
pandemic vaccine was prepared.
2. Vaccine-associated narcolepsy: the challenge
2.1. Time-course
For the A(H1N1) pandemic, the sequence and timing of events
(Fig. 1) illustrate the challenges facing health agencies in a
pandemic: 1) Initially, there was the identiﬁcation of a new circu-
lating A(H1N1) inﬂuenza virus (April 15, 2009). Following identi-
ﬁcation, the potential threat was escalated to the level of a global
pandemic due to its rapid and widespread transmission (June 11,
2009). 2) Vaccinemanufacturers responded to the urgent need for a
public vaccine by working with health agencies globally to identify,
isolate, and mass-produce millions of A(H1N1) pandemic vaccine
doses within a narrow window of time (April 24, 2009eNovember
29, 2009). The challenge of protecting large populations during a
pandemic underlie the reasons adjuvants were utilized to boost
vaccine efﬁcacy and vaccine supply through dose-sparing. 3)
Almost a year after the authorization of the pandemic vaccines in
Europe (September 2009), an increase in cases of narcolepsy was
detected with the European AS03-adjuvanted A(H1N1) pandemic
vaccine (August 18, 2010).
2.2. Epidemiology of narcolepsy with European AS03-adjuvanted
A(H1N1) pandemic vaccine
The ﬁrst suggestion of an association of narcolepsy with an
A(H1N1) pandemic vaccine was a case series released by the
Swedish Medical Agency reporting six adolescents (age 12e16
years) who developed narcolepsy following immunization with
European AS03-adjuvanted A(H1N1) pandemic vaccine [10].
Subsequently, Finland’s National Institute of Health and Welfare
detected an increased incidence of narcolepsy in children and
adolescents four to 19 years of age [11,12] associated with the useFig. 1. Sequence of events during 2009 A(H1N1) pandemic. For the A(H1N1)
pandemic, the sequence and timing of events illustrate the challenges facing health
agencies in a pandemic, the reasons adjuvants were utilized, and when a very rare
adverse event was detected.
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The incidence of narcolepsy was 9.0 in the vaccinated as
compared to 0.7/100,000 person years in unvaccinated in-
dividuals, the rate ratio was therefore 12.7, with an onset
approximately two months after vaccination [11]. Subsequently,
France, Ireland, Norway, and Sweden reported similar increases
in narcolepsy following the use of the European AS03-adjuvanted
A(H1N1) pandemic vaccine with VAESCO conﬁrming the initial
data from Finland and Sweden [13]. A similar report emerged
from the UK [14], and detailed follow-up studies in Sweden
[15,16] have further strengthened the initial association. Table 2
summarizes the key narcolepsy associations in various coun-
tries with the European AS03-adjuvanted A(H1N1) pandemic
vaccine, and more detailed surveillance information may be
found in a recent publication [17]. In addition to increased nar-
colepsy risk following vaccination in children and adolescents,
Finnish analyses of hospital and primary care data have demon-
strated a three to ﬁve-fold increased risk also in people aged 20
to 64 who received the European AS03-adjuvanted A(H1N1)
pandemic vaccine [18,19]. Of the 30 million doses of the European
AS03-adjuvanted A(H1N1) vaccine that were administered across
Europe, more than 800 were associated with narcolepsy devel-
opment [18]. The vaccine-attributable risk estimates from the
United Kingdom and Finnish studies range roughly between one
in 16,000 doses to one in 50,000 doses [14].
2.3. Implications and questions related to vaccines
The subsequent media attention has raised public awareness of
primary narcolepsy and stimulated new directions in research into
the pathological mechanisms of this complex neurologic sleep dis-
order [20] that annually affects 0.03e0.1% of the general population
[21]. One of the mechanisms postulated in primary narcolepsy is
dysregulation of the immune system and pathological autoimmunity
[22]. Since vaccine adjuvants are known to stimulate the immune
system and are key components in enhancing the response to
vaccination, could the adjuvant in the European AS03-adjuvanted
A(H1N1) pandemic vaccine have contributed to the narcolepsy-like
adverse events or was there another more probable mechanism?
3. Primary narcolepsy: understanding its pathophysiology
and triggers
3.1. Historical summary of various factors considered “associated”
with narcolepsy
Narcolepsy is a chronic disorder presenting with excessive day-
time sleepiness and often cataplexy, a transient loss of muscle toneTable 2
Summary of the narcolepsy associations with European AS03-adjuvanted A(H1N1) pand
Reporting country Report date Type of study Age groups
Sweden [109] June 2011 Case inventory study 19 years
Finland [11] March 2012 Retrospective cohort 4e19 years
Ireland [110] April 2012 Retrospective population-
based cohort
5e19 years
England [14] February 2013 Self-controlled cases series 4e18 years
Norway [111] June 2013 Registry-based 4e19 years
France [112] August 2013 Case-control Children (<18 yea
Adults (18 years)
a The general incidence of narcolepsy is 0.74e1.37 per 100,000 person years [17] but
b RR ¼ relative risk, CI ¼ conﬁdence interval, OR ¼ odds ratio.triggered by strong emotional stimuli. The ﬁrst description of
narcolepsy-cataplexywas in1877byWestphalwhoassociated itwith
repressed sexual identity and excessive sexual activity as the index
casewas an arrested rapist experiencing pathological sleepiness [23].
In 1888, Legrand noted (Fig. 2) the following association: “Encephalic
congestion resulting from cardiac deﬁciency, gastric troubles or hepatic
derangements, and such diseases as gout, diabetes, and rheumatism, are
some of its [narcolepsy’s] associations” [24]. Over 112 years transpired
between Legrand’s speculated associations with narcolepsy and the
scientiﬁc/medical observations [23] that culminated in Mignot’s dis-
covery in2000 that the protein hypocretinwasdeﬁcient due to loss of
hypothalamic cells in patients with narcolepsy [21,25].
3.2. Epidemiology
Narcolepsy-cataplexy is estimated to have a prevalence of 25e
50 per 100,000 people and an incidence of 0.74 per 100,000
person-years [26]. The prevalence of narcolepsy without cataplexy
has been estimated to be 20 to 34 per 100,000 people [27,28].
Observations from the United States, Canada, and Europe suggest
that half of adult narcolepsy patients reported onset prior to 15
years of age [29]. A report from China demonstrated that 70% of
narcolepsy patients had disease onset before age tenwhile 15% had
onset before six years of age [29]. The delay between onset and
diagnosis can be greater than ten years [30] but is reduced to only a
few years when disease onset occurs in childhood [31]. The pop-
ulation prevalence in China is 0.034% which is similar to the re-
ported prevalence rates in North America and Europe [29]. A
retrospective study of narcolepsy in subjects (86% children) diag-
nosed at one hospital in Beijing, China, demonstrated a three-fold
increase in narcolepsy diagnoses in 2010 following the A(H1N1)
inﬂuenza outbreak in 2009. The time to narcolepsy onset following
inﬂuenza infection was six months [32]. One would anticipate that
if the A(H1N1) pandemic inﬂuenza infection (the major circulating
strain in 2009) was a trigger for narcolepsy in China, there should
be a reduction of cases in the following years due to viral strain
replacement. Indeed, a follow-up report on new Chinese narco-
lepsy cases in 2011 and 2012 demonstrated a return to the prior
rates reported before the pandemic [33]. Yearly narcolepsy case
counts assessed from 2004 to 2010 in China demonstrated a trend
which paralleled circulating inﬂuenza infection [32], an environ-
mental risk factor signiﬁcantly associated with narcolepsy devel-
opment in a caseecontrol study reported in 2007 [34].
3.3. Is narcolepsy an autoimmune disease?
Hypocretin producing cells in the hypothalamus are lost in pa-
tients with narcolepsy, but it is not clear what triggers the cell loss,emic vaccine.
Associationsa Study period
Incidence of 4.2 cases per 100,000
(RRb ¼ 6.6, 95% CIb ¼ 3.1e14.5)
October 2009 to December 2010
Incidence of 9.0 cases per 100,000
(95% CIb 6.1e30.8)
January 2009 to December 2010
Incidence of 5.8 cases per 100,000
(95% CIb ¼ 3.5e9.0)
April 2009 to December 2010
Incidence of 9.9 cases per 100,000
(95% CIb ¼ 2.1e47.9)
October 2008 to December 2010
Incidence of 10 cases per 100,000
individuals (P < 0.0001, c-square)
November 2009 to January 2010
rs) Children ORb ¼ 6.5 (95% CIb ¼ 2.1e19.9)
Adult ORb ¼ 4.7 (95% CIb ¼ 1.6e13.9)
October 2009 to April 2011
3.84 per 100,000 person years for ages 10e19 [27].
Fig. 2. The original 1888 Lancet commentary related to narcolepsy: echoes from the
past. The association of narcolepsy with the European AS03-adjuvanted A(H1N1)
pandemic vaccine is currently creating public speculation about vaccine risk-beneﬁt. It
is ironic and noteworthy that a commentary on Legrand’s description of this disease in
1888 has immediately preceding it, on the same page, another commentary empha-
sizing the beneﬁt of vaccination and epidemiological studies for halting the smallpox
epidemic in Shefﬁeld, Britain, that infected 6000 people and resulted in 600 deaths.
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susceptible? Singh et al. [22] in 2013 summarized the information
to date regarding potential triggers and pathophysiology of nar-
colepsy and the possible role for autoimmunity despite the absence
of identiﬁed pathogenic autoantibodies. This lack of autoantibodies
contrasts with other autoimmune diseases affecting central ner-
vous system neurons [35]. While antibodies are one of the criteria
inWitebsky’s deﬁnition of autoimmune disease [36], this deﬁnition
does not exclude the role that cross-reactive T-cells might play in
deﬁning an autoimmune process. Such could be the case in nar-
colepsy. In a recent publication, CD4þ T-cell autoimmunity to
hypocretin and cross-reactivity to a hemagglutinin epitope in 2009
H1N1 inﬂuenza has been demonstrated with T-cells obtained from
individuals with narcolepsy and only disease-affected siblings from
identical twins discordant for narcolepsy [37]. Furthermore,carefully conducted genome wide association studies have impli-
cated alleles associated with T-cell receptor Va genes [38] and HLA
DQB1*06:02 in more than 85% of patients diagnosed with narco-
lepsy and cataplexy [22]. However, the presence of this HLA sub-
type in 12e38% of the general population not affected by
narcolepsy-cataplexy suggests the involvement of environmental
triggers or other genetic factors (both HLA and non-HLA) in nar-
colepsy development [39,40]. For example, individuals who
develop narcolepsy may have an overactive immune system that is
under the threshold for developing narcolepsy, but with adminis-
tration of the European AS03-adjuvanted A(H1N1) pandemic vac-
cine may have tipped towards the development of narcolepsy.
While autoimmunity may be a contributing factor in primary nar-
colepsy development, the trigger for this complex, multifactorial
disease is still unknown. The absence of this information limits an
evidence-based approach to the assessment of the role of the Eu-
ropean AS03-adjuvanted A(H1N1) pandemic vaccine in narcolepsy
development e leading to public speculation about the safety of
adjuvanted vaccines [41] since adjuvants enhance the response to
immunization by stimulating the immune system. Therefore, the
following sections will review the safety perspectives associated
with vaccines with and without adjuvants.
4. Vaccines: our evolving understanding of the immune
system
4.1. Vaccines and immune-mediated diseases
Three older-generation vaccines were associated with immune-
mediated diseases: 1) In the 1920s, rabies vaccine made from
phenolized sheep brain was associated with acute disseminated
encephalomyelitis in 0.1% of vaccine recipients [42]; 2) In the 1970s,
unadjuvanted “swine-ﬂu” vaccine had an estimable attributable
risk for Guillain-Barré neuritis of approximately one case per
100,000 vaccinations over a twelve-week interval following
vaccination [43]; and 3) in the 1990s, live, attenuated measles
vaccine (and measlesemumpserubella vaccine) were found to
have an associated risk of autoimmune thrombocytopenia of one
case in 30,000 vaccinations [44]. However, each of these associa-
tions must be considered within the context of risk from admin-
istering the vaccine versus risk related to acquiring the natural
infection. For example, the risk of autoimmune thrombocytopenia
with wild measles infection is ﬁve to ten-fold higher than that seen
with live, attenuated vaccine [44]. More recent studies with inﬂu-
enza vaccines have found a substantially lower risk of Guillain-
Barré Syndrome with only one to two cases per million doses [45]
while an increased risk has been seen following inﬂuenza-like ill-
nesses and other infections including Campylobacter jejuenei and/or
cytomegalovirus infections [46].
4.2. Vaccine types and related immune responses
Different vaccine types generate an immune response in
different ways including the following categories [47]: 1) vaccines
containing replicating virus/microbes that are modiﬁed to function
as an immunogen without causing disease in immune-competent
recipients (e.g., live attenuated vaccines); 2) vaccines containing
inactivated organisms that cannot replicate (e.g., split virion, sub-
unit, capsular polysaccharide, or conjugate vaccines); 3) vaccines
employing vectors (e.g., recombinant live-attenuated or
replication-deﬁcient viruses) that are nonpathogenic vehicles into
which genes from pathogens are inserted and from which those
genes are expressed [48]; and 4) vaccines composed of nucleic
acids (e.g., DNA [49] or RNA [49,50]) that are taken up by the vac-
cine recipient’s cells for synthesis of vaccine antigen that results in
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DNA [51,52], RNA [50], or vectored vaccines [53] to date, the
following section focuses on the former types.
Live vaccines, in general, consist of weakened replicating viruses
or bacteria that are able to elicit lifelong protectionwith one to two
doses (provided that the natural infection they are mimicking also
confers lifelong protection) and have minimal reactogenicity. Along
with these economical and logistical beneﬁts associated with
administering these vaccines (e.g., potentially relevant for countries
with limited ﬁnancial resources or limited access to subjects for
yearly vaccination), these vaccines elicit humoral immunity (anti-
bodies) and cellular immunity (T-cell mediated cytotoxicity). Ad-
juvants are not required. However, because of the delicate balance
between under and over-attenuation, live-vaccines are not tech-
nically feasible for many organisms and costs for developing new
ones are not practical given the existence of effective inactivated
vaccines. While it may be possible for the live vaccine virus or
bacteria to rarely revert to its disease-causing form and thus be
transmitted to other non-immune subjects [47], most live vaccines
do not. Due to their similarity in structure with the natural virus or
bacteria, live vaccines could induce molecular mimicry similar to
that associated with the natural infection [54,55]. However, during
development of a live vaccine, this concern of molecular mimicry is
carefully considered and vaccine candidates demonstrating these
attributes are screened for and excluded. Table 1 includes an
example of a live, attenuated vaccine for A(H1N1) pandemic
inﬂuenza.
In contrast to live vaccines, inactivated split-virion and subunit
vaccines do not carry replication-associated risks and are techni-
cally easier to produce. However, these vaccines usually require
multiple doses and then boosters to maintain long-term protective
immunity. They usually stimulate humoral immunity and build
the foundation (prime) for subsequent immunological memory
[52]. Enhancement of immunogenicity and stimulation of cellular
immunity (T-cell-mediated) usually requires the addition of ad-
juvants [6,47]. The degree to which inactivated vaccines are
tolerated depends on the extent of puriﬁcation to remove other
proteins associated with the infectious agent. One could purify
vaccines to enrich for protective antigens and limit the presence of
other proteins that might trigger side effects such as fever or
anaphylaxis (acutely) or immune-mediated diseases generated
through similarity with and cross-reactions to normal human
tissue (molecular mimicry) [56e59]. Table 1 includes some ex-
amples of inactivated split-virion and subunit vaccines for
A(H1N1) pandemic inﬂuenza.
5. Adjuvants: their role and demonstrated safety
5.1. Long-term experience
The safety of an adjuvant is paramount before assessing the
advantages of the immune enhancement they provide. Adjuvants
with extensive safety data based on long duration of use or
increased numbers of recipients include AS04 [60] and MF59 [61].
The AS04 adjuvant (that contains monophosphoryl lipid A
absorbed on aluminum) [60] is distinct from the AS03 adjuvant
(that contains DL a-tocopherol, squalene, and polysorbate 80) [62].
A large database of safety data has been accumulated for the AS04-
adjuvanted human papillomavirus vaccine licensed by the Food
and Drug Administration (FDA) in 2005 and approved in more than
110 countries. AS04 has demonstrated clinically the beneﬁt of
increased durability of vaccine-induced immune response (persis-
tence of high antibody titers after more than seven years) when
compared to vaccines adjuvanted with aluminum salt alone [60].
Furthermore, the AS04-adjuvanted hepatitis B vaccine authorizedby EMA in 2005 for pre-hemodialysis and hemodialysis patients
[63] has demonstrated that the use of AS04 enables a reduction in
antigen dose, earlier antibody response, and longer duration of
protective antibody titers compared with vaccines adjuvanted with
aluminum salt alone [60].
The MF59 adjuvant is a squalene-based adjuvant that is
different [64] from AS03 (Table 1). The MF59-adjuvanted
inﬂuenza vaccine has demonstrated a consistently robust safety
proﬁle [61] by way of the millions of doses distributed for use in
elderly subjects vaccinated since its licensure in 1997 in Italy.
MF59 has also demonstrated clinically the beneﬁt of dose
sparing [65] (e.g., reducing the amount of antigen needed so
more doses can be made available to the population when the
antigen is limited) and some cross-clade protection [66] (e.g.,
expanding coverage to include both infectious strain of interest
and potentially other related, but distinct, disease-causing inﬂu-
enza strains).
5.2. Recent experience
The adjuvants MF59 or AS03 have also recently been used in
distinct subsets of the population and have demonstrated their
utility and safety when added to inﬂuenza vaccines. These pop-
ulations comprise those deﬁned as vulnerable because of a naïve
immune system (children), immunosenescence (the elderly), or
physiological immunosuppression (pregnant women). For naïve
children, a clinical trial published in 2011 enrolling 269
children < six years of age demonstrated an absolute vaccine efﬁ-
cacy rate against all inﬂuenza strains of 86% in subjects receiving
MF59-adjuvanted trivalent inﬂuenza vaccine compared to 43% in
subjects receiving the non-adjuvanted vaccine [67]. For subjects
with immunosenescence [68], a recently published phase 3 ran-
domized study [69] of 43,695 subjects 65 years of age compared
non-adjuvanted and AS03-adjuvanted trivalent inﬂuenza vaccines.
A signiﬁcant reduction in all cause death and pneumonia was
demonstrated in elderly subjects receiving adjuvanted vaccine
despite failing tomeet prespeciﬁed superiority criteria compared to
non-adjuvanted seasonal vaccine [70]. For pregnant subjects, the
clinical safety experience with both MF59-adjuvanted A(H1N1)
pandemic vaccine [71,72] (n ¼ 2295 and n ¼ 7293 vaccinated
pregnant women, respectively) and AS03-adjuvanted A(H1N1)
pandemic vaccine [73] (n ¼ 267 vaccinated pregnant women) has
provided reassurance for their use in this population for which
infection with inﬂuenza virus poses a signiﬁcant risk of complica-
tions both for the mother and her fetus. The A(H1N1) pandemic
also serves as a reminder of why dose-sparing and earlier induction
of seroprotection is important e with the rapid human-to-human
transmission that occurred during the pandemic, traditional non-
adjuvanted vaccines would not have been able to meet re-
quirements for an adequate vaccine supply for the global popula-
tion nor would they have been able to establish a protective
response for the population at risk within the short window
available for immunization.
6. Autoimmune diseases: the time factor and clinical
experience with adjuvanted vaccines
6.1. Time factor
The delayed onset of secondary narcolepsy after vaccination
with the European AS03-adjuvanted A(H1N1) pandemic vaccine is
compatible with an immune-mediated process that typically re-
quires time to develop (particularly when an adaptive immune
response involving antibody and/or an antigen-speciﬁc T-cell
response is involved). There are precedents such as the intranasal
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Escherichia coli heat-labile toxin that is no longer in clinical use
because of the strong association with development of facial nerve
paralysis [74] (Bell’s palsy). The two hypotheses proposed for the
cause of primary Bell’s palsy are viral reactivation or cell-mediated
autoimmunity [75]. Interestingly, both of these mechanisms
are also being considered as causes for primary narcolepsy.
The cases associated with the intranasal virosomal subunit inﬂu-
enza vaccine had a maximal occurrence between 31 and 60 days
after vaccination suggesting that an induced adaptive immune
response to the vaccine led to the palsy rather than a direct acute
effect of the adjuvant [76]. However, could an adjuvant indepen-
dently induce autoimmune disease in a genetically predisposed
subject through immune system stimulation? What is known is
that immune-mediated stimulation occurring during natural in-
fections consistently triggers disease activity in patients with pre-
existing autoimmune disease [55,59,77,78]. In contrast to these
ﬁndings with natural infection, clinical studies using either non-
adjuvanted inﬂuenza vaccines [77,79,80] or inﬂuenza vaccines
adjuvanted with MF59 or AS03 in patients with autoimmune
disease have demonstrated no triggering of autoimmune disease
activity with the addition of these adjuvants to the vaccine [81e83].
Details on experience with adjuvanted vaccines given to in-
dividuals with various underlying diseases are described in the
next section.
6.2. Clinical experience with adjuvanted vaccines
For adult patients with inﬂammatory rheumatic diseases, two
recent prospective studies with either 94 adult patients immu-
nized with MF59-adjuvanted A(H1N1) pandemic vaccine [83] or
with 173 adult patients immunized with AS03-adjuvanted
A(H1N1) pandemic vaccine [81] demonstrated that the adju-
vanted vaccines were effective and safe. Furthermore, both studies
included patients with preexisting diagnoses for which well-
established and validated scoring systems were available to
measure disease activity (rheumatoid arthritis [RA], systemic
lupus erythematosus [SLE], spondylarthritis, or antineutrophil
cytoplasmic antibody-associated vasculitis) and demonstrated no
enhancement of underlying disease activity during the subsequent
follow-up in any disease group [81,83]. Of note, in the study with
AS03-adjuvanted A(H1N1) pandemic vaccine [81], patients
received not one, but two doses of the adjuvanted vaccine spaced
three to four weeks apart with no enhancement of underlying
disease activity. Biomarkers of autoimmune disease activity
remained unchanged in SLE patients on ﬁxed maintenance ther-
apies, and, in the case of RA, disease activity remained unchanged
even in those with active disease at the time of vaccination [81].
For pediatric patients with inﬂammatory rheumatic disease, a
recent study examined prospectively the effect of an MF59-
adjuvanted seasonal inﬂuenza vaccine in 60 pediatric patients
with juvenile idiopathic arthritis [82]. In addition to no evidence
of increased disease activity at one and three month follow-up
visits after vaccination, this clinical study demonstrated robust
safety and tolerability of a single-dose of the adjuvanted vaccine
that was similar to results obtained with healthy controls and
previous studies in the general pediatric population with MF59-
adjuvanted vaccine [67,84e87]. These studies provide evidence
that adjuvanted inﬂuenza vaccines can be safely administered to
older and younger patients with various types of underlying dis-
ease, thought to have an autoimmune component, without trig-
gering increased disease activity. Furthermore, extensive follow up
of normal subjects receiving MF59-adjuvanted inﬂuenza vaccines
have demonstrated no increase in the incidence of autoimmune
disease [61].7. Four clues supporting a hypothesis on the cause of A(H1N1)
inﬂuenza vaccine-associated narcolepsy?
7.1. Link between natural infection and autoimmune diseases
As mentioned earlier, immune-mediated stimulation occurring
during natural infections can trigger autoimmune disease activity
in patients. This is related to the major differences in the quality of
immune responses to natural infection when compared to that
induced by vaccines e a perspective of which is depicted in Fig. 3.
Natural infection has an increased degree (afﬁnity, amount, and
speciﬁcity isotype of antibodies; strength of T-cell response and the
cytokines that are elicited), longer duration, and greater dispersion
of inﬂammation. In comparison, vaccines are designed to have a
shorter duration of controlled immune stimulation that generates
minimal cell damage to the cells of the recipient providing a local
stimulus for triggering an immune response. Natural infections
may also stimulate molecular mimicry. The well-known condition
of Syndenham’s chorea in rheumatic fever provides good evidence
of inﬂammation and a cross-reaction between a microbe, b-he-
molytic streptococcus, and human antigens contained in basal
ganglia structures of the brain [88,89]. Fortunately, most humans
will tolerate potential autoimmune reactions (e.g., attack of self-
tissue) triggered by infection-associated molecular mimicry at the
T- and B-cell level in order to facilitate the removal of microbes that
have entered a normal cell. However, in certain subjects with a
speciﬁc genetic phenotype, the failure of regulatory mechanisms
allows this necessary autoimmunity of short duration to transform
into an unnecessary and chronic level of self-attack characterized
by clinical autoimmune disease [44]. Table 3 illustrates the various
autoimmune diseases that are hypothesized to be associated with
infection suggesting a role for molecular mimicry by the infectious
agent [90] in autoimmune disease development. While controlled
immune stimulation by an adjuvant is a critical component for
vaccine safety, the selection of vaccine antigens that avoid inclusion
of microbial proteins that may bemolecular mimics of autoantigens
is paramount.
While a recent publication [37] provides evidence for the ﬁn-
gerprints of an immune attack against a 2009 H1N1 inﬂuenza
virus component (an epitope from viral hemagglutinin), the
mimicry suggested between this epitope and hypocretin does not
explain the particular association of narcolepsy only with the
European-AS03 adjuvanted A(H1N1) pandemic vaccine. The viral
hemagglutinin was present in other adjuvanted A(H1N1)
pandemic vaccines including the Canadian-AS03 adjuvanted
A(H1N1) pandemic vaccine and the MF59 adjuvanted A(H1N1)
pandemic vaccine, and no increased risk for narcolepsy develop-
ment was observed with these vaccines [17]. The investigators’
speculation [37] that the strong stimulation of CD4þ T-cell re-
sponses by the AS03 adjuvant may have been responsible for
narcolepsy development is difﬁcult to reconcile mechanistically
given the lack of increased risk for narcolepsy with the Canadian-
AS03 adjuvanted A(H1N1) pandemic vaccine that used the same
AS03 adjuvant [17]. More plausible would be differences in H1N1
surface protein extraction protocols among vaccines as suggested
by the authors. Other molecular mimics may be contained in other
inﬂuenza proteins that are components of the European-AS03
adjuvanted A(H1N1) pandemic vaccine. The imprint of cross-
reactive antibodies to hypothalamic structures involved in the
production of hypocretin or its receptors, as well as cross-reactive
CD8 T-cell responses to such hypothalamic structures, remains to
be investigated. At present, it remains unproven whether a cross-
reactive autoimmune response to the hypocretin containing neu-
rons in the hypothalamus was triggered by the European-AS03
adjuvanted A(H1N1) pandemic vaccine.
Table 3
A few examples of infections hypothesized to be associated with autoimmune dis-
ease in humans.
Autoimmune disease Infection
Multiple sclerosis Herpes virus type 6 [113,114]
Guillain-Barré syndrome Campylobacter jejuni [115]
Mycoplasma pneumoniae [116]
Type 1 diabetes Cytomegalovirus [117,118]
Lyme arthritis Borrelia burgdorfeii [119,120]
Chagas disease/myocarditis Trypanosoma cruzi [121,122]
Fig. 3. Differences in inﬂammation from natural infection and that from immuniza-
tion. The greater degree, duration, and dispersion of inﬂammation from natural
infection (capable of triggering autoimmune disease activity) contrasted with the
shorter duration of controlled inﬂammation from vaccination (capable of triggering an
immune response).
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In the case of the A(H1N1) inﬂuenza vaccination campaign in
2009/10, there is an observation that may provide a clue as to the
vaccine component most likely responsible for the observed asso-
ciation with narcolepsy. The report that A(H1N1) pandemic inﬂu-
enza infection (natural disease) was shown in Beijing, China to be
associated with a three to four-fold rise in narcolepsy cases in the
absence of vaccination suggests a primary role for A(H1N1) inﬂu-
enza virus antigens in disease development [32]. While studies
outside China have not reported an increase in narcolepsy cases in
unvaccinated subjects, there may be a confounding factor that may
help to explain this discrepancy. Beijing is one of the most populous
cities of the world whose high residential density makes residents
highly susceptible to inﬂuenza [91]. This close proximity for
transmission of virus and the limited uptake of vaccines (1.36
million of the 70 million population received vaccine [92] ¼ 1.94%)
may have led to an increased and accelerated exposure of narco-
lepsy susceptible subjects to circulating A(H1N1) infection in
contrast to European populations not reporting an increase in
narcolepsy cases in unvaccinated subjects. This observation
potentially diminishes the role of the vaccine adjuvant in inde-
pendently triggering narcolepsy as the wild A(H1N1) pandemic
inﬂuenza infection apparently is all that is required for narcolepsy
to develop.7.3. Puriﬁcation processes used to isolate inﬂuenza vaccine antigens
for the adjuvanted pandemic vaccines and discordant associations
with narcolepsy e a second clue?
Different processes have been used in the manufacturing of the
different inactivated inﬂuenza pandemic vaccines containing ad-
juvants. Split-virion inﬂuenza vaccines, like the AS03-adjuvanted
A(H1N1) pandemic vaccine are produced by detergent-treating
inﬂuenza virus, and the splitting process breaks the virus allow-
ing the relevant antigens to be partially puriﬁed [93]. The split-
virion antigens contained in the two AS03-adjuvanted A(H1N1)
pandemic vaccines may differ as a consequence of site-speciﬁc
splitting/puriﬁcation procedures used (Dresden-protocol for the
European made Pandemrix and Quebec-protocol for Canadian
made Arepanrix). On the web page for the European Centre for
Disease Prevention and Control [13], information provided by the
manufacturer indicates that the Quebec protocol inactivated the
inﬂuenza virus by ultraviolet irradiation followed by formaldehyde,
then puriﬁed by centrifugation, followed by disruption with
deoxycholate. In the Dresden protocol, the virus is concentrated,
puriﬁed, detergent-treated, diaﬁltrated, and then inactivated by
deoxycholate and formaldehyde.
An estimated 30.8 million doses of European AS03-adjuvanted
A(H1N1) pandemic vaccine [13] were used in more than 47 coun-
tries starting in October 2009 with high coverage in some countries
including Finland, Sweden, Norway, and Ireland [1]. The Canadian
AS03-adjuvanted A(H1N1) pandemic vaccine was used with high
coverage in Canada where an estimated 12 million doses were
administered [1]. Detailed epidemiological studies are on-going in
Canada [13] to conﬁrm the initial ﬁndings of absence of narcolepsy
increase with this vaccine. Subunit or surface antigen inﬂuenza
vaccines like the MF59-adjuvanted A(H1N1) pandemic vaccine
involve inﬂuenza virus inactivation similar to split-virion vaccines
but then puriﬁcation is rigorously carried out so that the vaccine
consists almost exclusively of highly puriﬁed viral hemagglutinin
and neuraminidase [93]. An estimated 25 million doses of MF59
A(H1N1) adjuvanted vaccine were used in Europe and Latin
America [94] with no reported association, to date, with narcolepsy.
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pandemic vaccines: the third clue?
The absence of a narcolepsy signal with any of the non-
adjuvanted A(H1N1) pandemic inﬂuenza vaccines suggests that
A(H1N1) pandemic inﬂuenza antigens might have been preferen-
tially presented to the immune system in the presence of adjuvant.
This is intriguing when combined with the observation that wild
2009 A(H1N1) pandemic inﬂuenza infection in China was associ-
ated with increased narcolepsy. Both wild A(H1N1) pandemic
inﬂuenza virus and possibly the European AS03-adjuvanted
A(H1N1) pandemic vaccine may have enhanced A(H1N1)
pandemic inﬂuenza antigen presentation(s). Adjuvants may act in
several ways including: 1) delivering antigens to the immune sys-
tem, 2) enhancing the uptake of the antigen by antigen-presenting
cells (APCs), 3) allowing for progressive release, delayed clearance,
and better exposure to the immune system, or 4) inﬂuencing the
production of various cytokines produced in an immune response
[95e97]. All of which are desirable and expected effects with ad-
juvants. However, the nature of the stimulatory output generated
by the adjuvant depends on the antigen input. This antigen input
may differ based on how the vaccine was prepared as noted above
and may potentially explain why narcolepsy was not associated
with the MF59-adjuvanted A(H1N1) pandemic vaccine nor with
the AS03-adjuvanted A(H1N1) pandemic vaccine prepared in
Canada using the Quebec protocol. While one could also hypothe-
size that the differences in association with narcolepsy between
MF59 and AS03 might be due to their differing sites of action and
immune stimulatory effects as shown in mice [98,99], this would
not explainwhy two preparations of the AS03-adjuvanted A(H1N1)
pandemic vaccine differed in their associationwith narcolepsy (e.g.,
European versus Canadian inactivation/puriﬁcation protocol).
7.5. 1918 inﬂuenza pandemic and von Economo’s encephalitis
lethargica e the fourth clue?
The seasonal association of the 2009 A(H1N1) pandemic infec-
tion with subsequent narcolepsy in China may remind some of the
1918 inﬂuenza pandemic that was followed by a seasonal “sleepy
sickness” [100] that appeared to be a variant of a neurological
syndrome termed “von Economo’s encephalitis lethargica”. The
original syndrome involved drowsiness and cranial/peripheral
nerve involvement (eye abnormalities and facial paralysis) [101]
that was observed by von Economo during the Vienna winters of
1916e1917 and subsequently reported in 1918 [102]. The variants of
encephalitis lethargica occurring in association with the 1918
inﬂuenza epidemic included one with abrupt high fever, headache,
neck stiffness, lethargy, and fatality [103] or a more gradual one
resembling the original encephalitis lethargica syndrome but
demonstrating complete recovery in some cases [101] or with
development of a chronicmovement disorder in others [104]. What
is important to note are the following: 1) the causality of inﬂuenza
infection in triggering either the primary syndrome or its variants
has neither been proven nor disproven [103,105e107]; 2) some sort
of infection has been speculated to be associated with the variants
of encephalitis lethargica [103,108] that occurred during the
inﬂuenza pandemic of 1918e1921; and 3) both the inﬂuenza
pandemic and the neurological syndrome simultaneously subsided
in the following years from 1922 to 1925 [106].
8. Conclusions
Associations are the starting point for the generation of hy-
potheses that ultimately need validation with scientiﬁc, clinical,
and laboratory evidence. Careful, thoughtful assessment and moreresearch are needed to explain the observed increase in narcolepsy
with 2009 A(H1N1) pandemic inﬂuenza infection and with Euro-
pean AS03-adjuvanted A(H1N1) pandemic vaccine but not with the
MF59-adjuvanted A(H1N1) pandemic vaccine nor with the Ca-
nadian AS03-adjuvanted A(H1N1) pandemic vaccine. Examples of
some intriguing questions that remain unanswered for the time
being are 1) what would explain the differences in the suscepti-
bility to narcolepsy between children and adults and 2) why did not
all children with HLA DQB1*0602 develop narcolepsy after vacci-
nation? Possible answers for the ﬁrst question which are purely
speculative include the following: 1) naïve immune systems in
infants may peak in functional potency in children/adolescents and
plateau in adulthood heading toward immunosenescence in the
elderly. While a potent immune response would afford children/
adolescents protection against infections, it could also paradoxi-
cally allow for an easier unmasking of autoimmune disease in the
genetically predisposed subject or 2) the role of “germ theory” and
repetitive infections in adults that reﬁnes the immune response
into one that is precisely regulated and speciﬁc compared to the
more potent and primal immune response from children that
provokes autoimmunity when normal tissue is caught in the
“cross-ﬁre”. A speculative answer for the second question could be
that there is a still-undetermined environmental factor that, along
with the HLA susceptibility, triggers narcolepsy.
The authors would like to conclude this review by summarizing
the key points regarding what is known and has yet to be discov-
ered related to narcolepsy occurring in the setting of the A(H1N1)
pandemic:
1) The vaccine safety surveillance system effectively detected a
very rare adverse event (narcolepsy occurred in less than one
out of 10,000 vaccine recipients) in subjects receiving AS03
adjuvanted A(H1N1) pandemic vaccine made using the Euro-
pean inactivation/puriﬁcation protocol; but the trigger for this
very rare adverse event is not yet clear.
2) The association of wild A(H1N1) pandemic inﬂuenza infection
with narcolepsy suggests a role for the viral antigen(s) in disease
development.
3) While a recent investigation demonstrated a role for T-cell
cross-reactivity between an inﬂuenza hemagglutin epitope and
hypocretin, there is no evidence, to date, that vaccine-associated
narcolepsy is an autoimmune phenomenon mediated by auto-
antibodies to hypocretin.
4) While studies on antibodies to hypocretin and T-cell subsets
have been conducted in primary narcolepsy, more conclusive
work is needed to better understand the pathophysiology
including investigations into T-cell responses and identiﬁcation
of what factor(s) in wild A(H1N1) pandemic inﬂuenza infection
trigger(s) primary narcolepsy in susceptible hosts.
5) As no similar association has been reported to date with the
AS03-adjuvanted A(H1N1) pandemic vaccine made using the
Canadian inactivation/puriﬁcation protocol, this suggests that
the AS03 adjuvant alone may not be responsible for the narco-
lepsy association. No similar association has been reported to
date with an MF59-adjuvanted A(H1N1) pandemic vaccine.
6) Careful and long-term epidemiological studies including follow-
up of children and adults who developed narcolepsy in associa-
tionwith AS03-adjuvanted A(H1N1) pandemic vaccine prepared
with the European inactivation/puriﬁcation protocol are needed.
7) Further studies are needed to determine if the ebbs and ﬂows in
narcolepsy incidence observed with wild A(H1N1) pandemic
inﬂuenza infection in China are demonstrated elsewhere and if
decreasing the risk of inﬂuenza infection with vaccination in
those at highest risk helps to decrease the incidence of
narcolepsy.
S.S. Ahmed et al. / Journal of Autoimmunity 50 (2014) 1e11 9Acknowledgments
The authors would like to acknowledge Nicola Groth, MD, PhD
for clinical trial experience and epidemiological expertise related to
pediatric and elderly inﬂuenza, Gervais Tougas, MD for pharma-
covigilance expertise and critical review of the manuscript, and
Giorgio Corsi for his assistance with artwork related to the ﬁgures.References
[1] European Center for Disease Prevention and Control. Enhanced monitoring
of vaccine safety for 2009 pandemic vaccines. Available from: URL: http://
www.ecdc.europa.eu/en/healthtopics/pandemic_preparedness/2009_
pandemic_vaccines/Pages/vaccine-safety.aspx; 2013 February 27.
[2] U.S.Food and Drug Administration. Approved products: inﬂuenza A (H1N1)
2009 monovalent. U S Department of Health & Human Services; 2010
January 15. Available from: http://www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm181950.htm.
[3] Kendal AP, MacDonald NE. Inﬂuenza pandemic planning and performance in
Canada, 2009. Can J Public Health 2010 November;101(6):447e53.
[4] GlaxoSmithKline Inc. Drugs and health products: inﬂuenza A (H1N1) 2009
pandemic monovalent vaccine (without adjuvant). Health Canada; 2013 June
24. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/
legislation/interimorders-arretesurgence/prodinfo-vaccin-na-eng.php.
[5] European Centre for Disease Prevention and Control. Narcolepsy in associ-
ation with pandemic inﬂuenza vaccination (a multi-country European
epidemiological investigation). Stockholm. Available from: http://www.ecdc.
europa.eu/en/publications/publications/vaesco%20report%20ﬁnal%20with%
20cover.pdf; 2012 Sep.
[6] Ahmed SS, Plotkin SA, Black S, Coffman RL. Assessing the safety of adjuvanted
vaccines. Sci Transl Med 2011 July 27;3(93):93rv2.
[7] Andrews N, Stowe J, Miller E, Svanstrom H, Johansen K, Bonhoeffer J, et al.
A collaborative approach to investigating the risk of thrombocytopenic
purpura after measles-mumps-rubella vaccination in England and Denmark.
Vaccine 2012 April 19;30(19):3042e6.
[8] Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al.
Vaccine Safety Datalink project: a new tool for improving vaccine safety
monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics
1997 June;99(6):765e73.
[9] Eurosurveillance editorial team. ECDC in collaboration with the VAESCO
consortium to develop a complementary tool for vaccine safety monitoring
in Europe. Euro Surveill 2009 September 10;14(39).
[10] Lakemedelsverket Medical Products Agency. The MPA investigates reports of
narcolepsy in patients vaccinated with Pandemrix. Available from: http://
www.lakemedelsverket.se/english/All-news/NYHETER-2010/The-MPA-
investigates-reports-of-narcolepsy-in-patients-vaccinated-with-Pandemrix/
; 2010 August 18.
[11] Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al.
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the
incidence of childhood narcolepsy in Finland. PLoS One 2012;7(3):e33536.
[12] Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P,
et al. Increased incidence and clinical picture of childhood narcolepsy
following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS
One 2012;7(3):e33723.
[13] European Centre for Disease Prevention and Control. Association of receipt of




2FLists%2FECDC%20Reviews; 2013 March 18.
[14] Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al.
Risk of narcolepsy in children and young people receiving AS03 adjuvanted
pandemic A/H1N1 2009 inﬂuenza vaccine: retrospective analysis. Br Med J
2013;346:f794.
[15] Persson I, Feltelius N. Registry study conﬁrms increased risk of narcolepsy
after vaccination with Pandemrix in children and adolescents and shows an
increased risk in young adults. Lakemedelsverket Medical Products Agency;




[16] Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy
in western Sweden after H1N1 inﬂuenza vaccination. Neurology 2013 April
2;80(14):1315e21.
[17] Barker CI, Snape MD. Pandemic inﬂuenza A H1N1 vaccines and narcolepsy:
vaccine safety surveillance in action. Lancet Infect Dis 2013 Dec 18. http://
dx.doi.org/10.1016/S1473-3099(13)70238-X. pii: S1473-3099(13)70238-X.
[Epub ahead of print].
[18] Ando R, Kelland K. GSK ﬂu shot may raise adult narcolepsy risk: Finnish
scientists. Reuters; 2013 May 23. Available from: http://www.reuters.com/
article/2013/05/23/us-gsk-vaccine-narcolepsy-idUSBRE94M0FJ20130523.[19] Jokinen J, Nohynek H. Increased risk of narcolepsy observed also among
adults vaccinated with Pandemrix in Finland. Finland: National Institute for
Health and Welfare; 2013 May 23. Available from: http://www.thl.ﬁ/doc/en/
33516.
[20] Luca G, Haba-Rubio J, Dauvilliers Y, Lammers GJ, Overeem S, Donjacour CE,
et al. Clinical, polysomnographic and genome-wide association analyses of
narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep
Res 2013 October;22(5):482e95. http://dx.doi.org/10.1111/jsr.12044. Epub
2013 Mar 18.
[21] Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin)
deﬁciency in human narcolepsy. Lancet 2000 January 1;355(9197):39e40.
[22] Singh AK, Mahlios J, Mignot E. Genetic association, seasonal infections and
autoimmune basis of narcolepsy. J Autoimmun 2013 June;43:26e31. http://
dx.doi.org/10.1016/j.jaut.2013.02.003. Epub 2013 Mar 13.
[23] Mignot E. A hundred years of narcolepsy research. Arch Ital Biol 2001
April;139(3):207e20.
[24] Lancet communication. Narcolepsy; 1888 Jan 28. Report No.: 131.
[25] Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al.
A mutation in a case of early onset narcolepsy and a generalized absence of
hypocretin peptides in human narcoleptic brains. Nat Med 2000
September;6(9):991e7.
[26] Longstreth Jr WT, Koepsell TD, Ton TG, Hendrickson AF, van BG. The
epidemiology of narcolepsy. Sleep 2007 January;30(1):13e26.
[27] Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy
in Olmsted County, Minnesota: a population-based study. Sleep 2002 March
15;25(2):197e202.
[28] Shin YK, Yoon IY, Han EK, No YM, Hong MC, Yun YD, et al. Prevalence of
narcolepsy-cataplexy in Korean adolescents. Acta Neurol Scand 2008
April;117(4):273e8.
[29] Han F, Lin L, Li J, Aran A, Dong SX, An P, et al. Presentations of primary
hypersomnia in Chinese children. Sleep 2011 May;34(5):627e32.
[30] Morrish E, King MA, Smith IE, Shneerson JM. Factors associated with a delay
in the diagnosis of narcolepsy. Sleep Med 2004 January;5(1):37e41.
[31] Nevsimalova S. Narcolepsy in childhood. Sleep Med Rev 2009 April;13(2):
169e80.
[32] Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is
seasonal and increased following the 2009 H1N1 pandemic in China. Ann
Neurol 2011 September;70(3):410e7.
[33] Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood nar-
colepsy 2 years after the 2009 H1N1 winter ﬂu pandemic. Ann Neurol 2012
November 9. http://dx.doi.org/10.1002/ana.23799 [Epub ahead of print].
[34] Picchioni D, Hope CR, Harsh JR. A case-control study of the environmental
risk factors for narcolepsy. Neuroepidemiology 2007;29(3e4):185e92.
[35] Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of
the CNS. J Neurol 2010 April;257(4):509e17.
[36] Rose NR, Bona C. Deﬁning criteria for autoimmune diseases (Witebsky’s
postulates revisited). Immunol Today 1993 September;14(9):426e30.
[37] De la Herran-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, et al.
CD4þ T cell autoimmunity to Hypocretin/Orexin and cross-reactivity to a
2009 H1N1 inﬂuenza a epitope in narcolepsy. Sci Transl Med 2013 December
18;5(216). 216ra176.
[38] Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, et al.
Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat
Genet 2009 June;41(6):708e11.
[39] Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al. Complex HLA-DR and
-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
Am J Hum Genet 2001 March;68(3):686e99.
[40] Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, Donjacour CE, et al.
Genome-wide association study identiﬁes newHLA class II haplotypes strongly
protective against narcolepsy. Nat Genet 2010 September;42(9):786e9.
[41] Kelland K. Insight: GSK vaccine ingredient scrutinized for narcolepsy clues.
Reuters; 2013 February 8. Available from: http://www.reuters.com/article/
2013/02/08/us-narcolepsy-vaccine-adjuvant-idUSBRE91708V20130208.
[42] Baxter AG. The origin and application of experimental autoimmune
encephalomyelitis. Nat Rev Immunol 2007 November;7(11):904e12.
[43] Palese P, Ritchey MB, Schulman JL, Kilbourne ED. Genetic composition of a
high-yielding inﬂuenza A virus recombinant: a vaccine strain against
“Swine” inﬂuenza. Science 1976 October 15;194(4262):334e5.
[44] Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease:
what is the evidence? Lancet 2003 November 15;362(9396):1659e66.
[45] Baxter R, Bakshi N, Fireman B, Lewis E, Ray P, Vellozzi C, et al. Lack of as-
sociation of guillain-barre syndrome with vaccinations. Clin Infect Dis 2013
July;57(2):197e204.
[46] Salmon DA, Halsey NA. Editorial commentary: guillain-barre syndrome and
vaccinations. Clin Infect Dis 2013 July;57(2):205e7.
[47] Ellis R, Rappuoli R, Ahmed S. Technologies for making new vaccines. In:
Plotkin SA, Orenstein WA, Ofﬁt PA, editors. Vaccines. 6th ed. Edinburgh:
Elsevier/Saunders; 2013. pp. 1182e99.
[48] Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009
December;16(12):1709e19.
[49] Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles,
progress and prospects. Vaccine 1999 December 10;18(9e10):765e77.
[50] Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral
delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012
September 4;109(36):14604e9.
S.S. Ahmed et al. / Journal of Autoimmunity 50 (2014) 1e1110[51] Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet
2008 October;9(10):776e88.
[52] Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical
applications of DNA vaccines: current progress. Clin Infect Dis 2011 August
1;53(3):296e302.
[53] Lambe T. Novel viral vectored vaccines for the prevention of inﬂuenza. Mol
Med 2012;18:1153e60.
[54] Delogu LG, Deidda S, Delitala G, Manetti R. Infectious diseases and autoim-
munity. J Infect Dev Ctries 2011 October;5(10):679e87.
[55] Rose NR. The role of infection in the pathogenesis of autoimmune disease.
Semin Immunol 1998 February;10(1):5e13.
[56] Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L,
Warren KG. Recognition of the immunodominant myelin basic protein
peptide by autoantibodies and HLA-DR2-restricted T cell clones from mul-
tiple sclerosis patients. Identity of key contact residues in the B-cell and T-
cell epitopes. J Clin Invest 1997 September 1;100(5):1114e22.
[57] Steinman L, Oldstone MB. More mayhem from molecular mimics. Nat Med
1997 December;3(12):1321e2.
[58] Ruiz PJ, Garren H, Hirschberg DL, Langer-Gould AM, Levite M, KarpujMV, et al.
Microbial epitopes act as altered peptide ligands to prevent experimental
autoimmune encephalomyelitis. J Exp Med 1999 April 19;189(8):1275e84.
[59] Bach JF. The effect of infections on susceptibility to autoimmune and allergic
diseases. N Engl J Med 2002 September 19;347(12):911e20.
[60] Garcon N, Segal L, Tavares F, Van MM. The safety evaluation of adjuvants
during vaccine development: the AS04 experience. Vaccine 2011 June
15;29(27):4453e9.
[61] Pellegrini M, Nicolay U, Lindert K, Groth N, Della CG. MF59-adjuvanted
versus non-adjuvanted inﬂuenza vaccines: integrated analysis from a large
safety database. Vaccine 2009 November 16;27(49):6959e65.
[62] Roman F, Vaman T, Kafeja F, Hanon E, Van DP. AS03(A)-Adjuvanted inﬂuenza
A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010
September 15;51(6):668e77.
[63] GlaxoSmithKline Biologicals. Fendrix: EPAR - product information. Available
from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/000550/WC500021704.pdf; 2013 February 23.
[64] Tsai T, Del GG, Crucitti A, Weil J, Narasimhan V. Is the adjuvant solely to
blame? Br Med J 2013;346:f2375.
[65] Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, Del GG, et al.
Inﬂuenza vaccine immunology. Immunol Rev 2011 January;239(1):167e77.
[66] Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al.
MF59 adjuvant enhances diversity and afﬁnity of antibody-mediated im-
mune response to pandemic inﬂuenza vaccines. Sci Transl Med 2011 June
1;3(85). 85ra48.
[67] Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, et al.
Enhanced immunogenicity of seasonal inﬂuenza vaccines in young children
using MF59 adjuvant. Pediatr Infect Dis J 2009 July;28(7):563e71.
[68] Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and mea-
surement in inﬂuenza vaccine response among the elderly. Vaccine 2007
April 20;25(16):3066e9.
[69] McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, et al.
AS03-adjuvanted versus non-adjuvanted inactivated trivalent inﬂuenza
vaccine against seasonal inﬂuenza in elderly people: a phase 3 randomised
trial. Lancet Infect Dis 2013 June;13(6):485e96. http://dx.doi.org/10.1016/
S1473-3099(13)70046-X. Epub 2013 Mar 19.
[70] Ledgerwood JE. AS03-adjuvanted inﬂuenza vaccine in elderly people. Lancet
Infect Dis 2013 June;13(6):466e7. http://dx.doi.org/10.1016/S1473-
3099(13)70038-0. Epub 2013 Mar 19.
[71] Heikkinen T, Young J, van BE, Franke H, Verstraeten T, Weil JG, et al. Safety of
MF59-adjuvanted A/H1N1 inﬂuenza vaccine in pregnancy: a comparative
cohort study. Am J Obstet Gynecol 2012 September;207(3):177e8.
[72] Rubinstein F, Micone P, Bonotti A, Wainer V, Schwarcz A, Augustovski F, et al.
Inﬂuenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse
perinatal outcomes: multicentre study. Br Med J 2013;346:f393.
[73] Tavares F, Nazareth I, Monegal JS, Kolte I, Verstraeten T, Bauchau V. Preg-
nancy and safety outcomes in women vaccinated with an AS03-adjuvanted
split virion H1N1 (2009) pandemic inﬂuenza vaccine during pregnancy: a
prospective cohort study. Vaccine 2011 August 26;29(37):6358e65.
[74] Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the
inactivated intranasal inﬂuenza vaccine and the risk of Bell’s palsy in
Switzerland. N Engl J Med 2004 February 26;350(9):896e903.
[75] Greco A, Gallo A, Fusconi M, Marinelli C, Macri GF, de VM. Bell’s palsy and
autoimmunity. Autoimmun Rev 2012 December;12(2):323e8.
[76] Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell’s palsy.
N Engl J Med 2004 February 26;350(9):860e1.
[77] Stojanovich L. Inﬂuenza vaccination of patients with systemic lupus ery-
thematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 2006
June;13(2e4):373e5.
[78] Hemauer A, Beckenlehner K, Wolf H, Lang B, Modrow S. Acute parvovirus
B19 infection in connection with a ﬂare of systemic lupus erythematodes in a
female patient. J Clin Virol 1999 September;14(1):73e7.
[79] Brodman R, Gilﬁllan R, Glass D, Schur PH. Inﬂuenzal vaccine response in
systemic lupus erythematosus. Ann Intern Med 1978 June;88(6):735e40.
[80] Milanovic M, Stojanovich L, Djokovic A, Kontic M, Gvozdenovic E. Inﬂuenza
vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med
2013;229(1):29e34.[81] Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact
of synthetic and biologic disease-modifying antirheumatic drugs on antibody
responses to the AS03-adjuvanted pandemic inﬂuenza vaccine: a prospec-
tive, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011
June;63(6):1486e96.
[82] Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunoge-
nicity, safety and tolerability of MF59-adjuvanted seasonal inﬂuenza vaccine
in children with juvenile idiopathic arthritis. Vaccine 2012 January 20;30(5):
936e40.
[83] Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al.
Efﬁcacy and safety of vaccination against pandemic 2009 inﬂuenza A (H1N1)
virus among patients with rheumatic diseases. Arthritis Care Res Hob 2011
July;63(7):1062e7.
[84] Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful
tool to enhance and broaden protection against seasonal inﬂuenza viruses in
subjects at risk. Expert Opin Biol Ther 2010 April;10(4):639e51.
[85] Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, et al. Inﬂuenza A/
H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23
months. Pediatrics 2011 May;127(5):e1161e8.
[86] Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-
adjuvanted inﬂuenza vaccine (FLUAD) in children: safety and immunoge-
nicity following a second year seasonal vaccination. Vaccine 2009 October
23;27(45):6291e5.
[87] Esposito S, Principi N. Different inﬂuenza vaccine formulations and adjuvants
for childhood inﬂuenza vaccination. Vaccine 2011 October 6;29(43):7535e
41.
[88] Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry
and antibody-mediated cell signaling in the pathogenesis of Sydenham’s
chorea. Autoimmunity 2006 February;39(1):21e9.
[89] Dale RC, Church AJ, Cardoso F, Goddard E, Cox TC, Chong WK, et al. Post-
streptococcal acute disseminated encephalomyelitis with basal ganglia
involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol
2001 November;50(5):588e95.
[90] Rose NR, Mackay IR. Molecular mimicry: a critical look at exemplary in-
stances in human diseases. Cell Mol Life Sci 2000 April;57(4):542e51.
[91] Wu S, Yang P, Li H, Ma C, Zhang Y, Wang Q. Inﬂuenza vaccination coverage
rates among adults before and after the 2009 inﬂuenza pandemic and the
reasons for non-vaccination in Beijing, China: a cross-sectional study. BMC
Public Health 2013;13:636.
[92] Wang X, Yang P, Seale H, Zhang Y, Deng Y, Pang X, et al. Estimates of the true
number of cases of pandemic (H1N1) 2009, Beijing, China. Emerg Infect Dis
2010 November;16(11):1786e8.
[93] Hickling J, D’Hondt E. A review of production technologies for inﬂuenza virus
vaccine, and their suitability for deployment in developing countries for
inﬂuenza pandemic preparedness. Geneva, Switzerland: World Health Or-
ganization Initiative for Vaccine Research; 2006 Dec 20. Available from:
http://www.yumpu.com/en/document/view/5302692/a-review-of-
production-technologies-for-world-health-organization.
[94] Tsai TF. MF59 adjuvanted seasonal and pandemic inﬂuenza vaccines. Yaku-
gaku Zasshi 2011;131(12):1733e41.
[95] Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve
the immune response. Vaccine 2010 August 31;28(Suppl. 3):C25e36.
[96] Braun LJ, Eldridge AM, Cummiskey J, Arthur KK, Wuttke DS. The role of
adjuvant in mediating antigen structure and stability. J Pharm Sci 2012
April;101(4):1391e9.
[97] Garcon N, Chomez P, Van MM. GlaxoSmithKline adjuvant systems in vac-
cines: concepts, achievements and perspectives. Expert Rev Vaccines 2007
October;6(5):723e39.
[98] O’Hagan DT, Ott GS, De GE, Seubert A. The mechanism of action of MF59-an
innately attractive adjuvant formulation. Vaccine 2012 June 19;30(29):
4341e8.
[99] Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al.
Adjuvant system AS03 containing alpha-tocopherol modulates innate im-
mune response and leads to improved adaptive immunity. Vaccine 2011
March 16;29(13):2461e73.
[100] Vilensky JA, Foley P, Gilman S. Children and encephalitis lethargica: a his-
torical review. Pediatr Neurol 2007 August;37(2):79e84.
[101] Alexander JB. Cases resembling encephalitis lethargica occurring during the
inﬂuenza epidemic. Br Med J 1919 June 28;1(3052):794e5.
[102] Von Economo C. Die encephalitis lethargica. Leipzig: Franz Deuticke; 1918.
[103] Brasher CW, Caldwell JR, Coombe EJ. A report on two cases of encephalitis
lethargica. Br Med J 1919 June 14;1(3050):733e4.
[104] Buzzard EF. Encephalitis lethargica. Proc R Soc Med 1919;12:56e64 (Neurol
Sect).
[105] Hunter C. The late dequelae of encephalitis lethargica and of inﬂuenza. Can
Med Assoc J 1931 June;24(6):828e30.
[106] McCall S, Vilensky JA, Gilman S, Taubenberger JK. The relationship between
encephalitis lethargica and inﬂuenza: a critical analysis. J Neurovirol 2008
May;14(3):177e85.
[107] Foley PB. Encephalitis lethargica and the inﬂuenza virus. II. The inﬂuenza
pandemic of 1918/19 and encephalitis lethargica: epidemiology and symp-
toms. J Neural Transm 2009 October;116(10):1295e308.
[108] Maurizi CP. Inﬂuenza caused epidemic encephalitis (encephalitis lethargica):
the circumstantial evidence and a challenge to the nonbelievers. Med Hy-
potheses 2010 May;74(5):798e801.
S.S. Ahmed et al. / Journal of Autoimmunity 50 (2014) 1e11 11[109] Lakemedelsverket Medical Products Agency. Occurrence of narcolepsy with
cataplexy among children and adolescents in relation to the H1N1 pandemic
and Pandemrix vaccinations e results of a case inventory study by the MPA
in Sweden during 2009-2010. Sweden. Available from: http://www.
lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_
pandermrix_110630.pdf; 2011 Jun 30.
[110] O’Flanagan D, Bonner C, Crowe C, Lynch B, Sweeney B, Gilvarry J, et al.
Investigation of an increase in the incidence of narcolepsy in children and
adolescents in 2009 and 2010. Available from: http://healthupdate.gov.ie/
wp-content/uploads/2012/04/Final_Report_of_National_Narcolepsy_Study_
Steering_Committee-latest1.pdf; 2012 Apr 19.
[111] Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, et al.
Incidence of narcolepsy in Norwegian children and adolescents after vacci-
nation against H1N1 inﬂuenza A. Sleep Med 2013 September;14(9):867e71.
[112] Dauvilliers Y, Arnulf I, Lecendreux M, Monaca CC, Franco P, Drouot X, et al.
Increased risk of narcolepsy in children and adults after pandemic H1N1
vaccination in France. Brain 2013 August;136(Pt 8):2486e96.
[113] Steinman L. Multiple sclerosis: a coordinated immunological attack against
myelin in the central nervous system. Cell 1996 May 3;85(3):299e302.
[114] Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al.
Plaque-associated expression of human herpesvirus 6 in multiple sclerosis.
Proc Natl Acad Sci U S A 1995 August 1;92(16):7440e4.[115] Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL.
Lipopolysaccharides from Campylobacter jejuni associated with Guillain-
Barre syndrome patients mimic human gangliosides in structure. Infect
Immun 1994 May;62(5):2122e5.
[116] AngCW,Tio-GillenAP,Groen J,HerbrinkP, JacobsBC,VanKR,etal.Cross-reactive
anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in
Guillain-Barre syndrome. J Neuroimmunol 2002 September;130(1e2):179e83.
[117] Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus
infection with autoimmune type 1 diabetes. Lancet 1988 July 2;2(8601):1e4.
[118] Fairweather D, Rose NR. Type 1 diabetes: virus infection or autoimmune
disease? Nat Immunol 2002 April;3(4):338e40.
[119] Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann
Intern Med 1987 November;107(5):725e31.
[120] Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of
Borrelia burgdorferi DNA by polymerase chain reaction in synovial ﬂuid from
patients with Lyme arthritis. N Engl J Med 1994 January 27;330(4):229e34.
[121] Pereira JB, Wilcox HP, Coura JR. The evolution of chronic chagasic cardiop-
athy. I. The inﬂuence of parasitemia. Rev Soc Bras Med Trop 1992
April;25(2):101e8.
[122] Elias FE, Vigliano CA, Laguens RP, Levin MJ, Berek C. Analysis of the presence
of Trypanosoma cruzi in the heart tissue of three patients with chronic
Chagas’ heart disease. Am J Trop Med Hyg 2003 February;68(2):242e7.
